Fingerprint
Dive into the research topics of 'Six-month progression-free survival as an alternative primary efficacy endpoint to overall survival in newly diagnosed glioblastoma patients receiving temozolomide'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically